Having already got off to a strong start on the US market on the back of stellar progression-free survival data, AstraZeneca’s immunotherapy Imfinzi has hit a second primary endpoint of the PACIFIC trial by improving overall survival in unresectable Stage III NSCLC patients, raising the bar even higher for future competition from rival PD-1/L1 inhibitors.
Fresh data from the key PACIFIC trial showing that Imfinzi (durvalumab) significantly improves overall survival (OS) in patients with earlier stage non-small cell lung cancer (NSCLC) has placed AstraZeneca PLC further ahead of the chasing checkpoint inhibitor pack in this indication.
The company has announced that a planned interim analysis conducted by an independent data monitoring committee concluded that the Phase...
The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.
The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
